AstraZeneca Pharmaceuticals LP
NEWS
Several employees at three biopharma firms are not having a very good week, as Zealand Pharma, Merck and Orchard Therapeutics all announced job cuts.
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
AstraZeneca shared that using imfinzi alongside chemoradiotherapy did not meet statistical significance in improving progression-free survival versus using CRT alone.
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
BMS filed a patent infringement lawsuit against AstraZeneca over Imfinzi, while Guardant Health issued a statement in response to Illumina’s intellectual property lawsuit.
It was a busy week for clinical trial announcements. Here’s a look.
Sir Mene Pangalos said the company was considering not submitting it to the FDA if it finds it is “banging its head against a brick wall indefinitely.”
Alexion will pay Chugai $775 million in the second quarter of 2022 in exchange for the Japanese firm withdrawing the patent infringement lawsuits it filed in Europe, Japan and the U.S.
JOBS
IN THE PRESS